Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Ibrutinib inhibits Bruton tyrosine kinase while venetoclax is a specific inhibitor of the anti-apoptotic protein BCL2. Both drugs are highly effective as monotherapy against chronic lymphocytic leukemia (CLL), and clinical trials using the combination therapy have produced remarkable results in term...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Pin, Wang, Shengchun, Franzen, Carrie A., Venkataraman, Girish, McClure, Rebecca, Li, Lei, Wu, Wenjun, Niu, Nifang, Sukhanova, Madina, Pei, Jianming, Baldwin, Donald A., Nejati, Reza, Wasik, Mariusz A., Khan, Nadia, Tu, Yifan, Gao, Juehua, Chen, Yihua, Ma, Shuo, Larson, Richard A., Wang, Y. Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893066/
https://www.ncbi.nlm.nih.gov/pubmed/33602908
http://dx.doi.org/10.1038/s41408-021-00429-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893066/
https://www.ncbi.nlm.nih.gov/pubmed/33602908
http://dx.doi.org/10.1038/s41408-021-00429-z

Ejemplares similares